Study guide

10.10 Substance Use, Withdrawal and Cardiac Effects

AACN Cardiac Medicine Certification CMC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview and the CMC Test Plan

1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them

2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease

2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy

3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease

3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup

4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions

4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation

5 Chapter 5: Vascular Conditions and Vascular Interventions

5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications

6 Chapter 6: Shock States and Mechanical Circulatory Support

6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD

7 Chapter 7: Cardiac Procedures and Structural Heart Interventions

7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications

8 Chapter 8: Cardiovascular Pharmacology

8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure

9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary

9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients

10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral

10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients

11 Chapter 11: Monitoring and Diagnostics

11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography

12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions

12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease

10.10 Substance Use, Withdrawal and Cardiac Effects

Key Takeaways Explain This Topic AI

Benzodiazepines are first-line for cocaine-associated chest pain and hypertension; beta blockers are avoided acutely because of unopposed alpha-mediated vasoconstriction, and QRS widening beyond 100-120 ms is treated with sodium bicarbonate 1-2 mEq/kg.

Alcohol withdrawal follows a predictable clock: tremor and autonomic hyperactivity at 6-24 hours, seizures at 12-48 hours, alcoholic hallucinosis at 12-24 hours with an intact sensorium, and delirium tremens at 48-96 hours.

Symptom-triggered benzodiazepine dosing guided by the CIWA-Ar (treat at a score of 8-10 or above) reduces total benzodiazepine exposure and withdrawal duration compared with fixed schedules.

Naloxone is titrated in 0.04-0.4 mg IV increments in an opioid-dependent patient because full reversal precipitates a catecholamine surge that can produce hypertension, tachycardia and flash pulmonary edema.

Methadone causes dose-dependent QT prolongation, and injection drug use is the dominant driver of right-sided (tricuspid) Staphylococcus aureus endocarditis with septic pulmonary emboli.

Last updated: August 2026

Cocaine and Methamphetamine

Test-plan item II.G.1 is dominated by stimulants, because cocaine is a leading cause of drug-related chest pain in adults under 45 and because its management contradicts the reflexes of a cardiac nurse.

Mechanism — Four Simultaneous Insults

Blockade of norepinephrine, dopamine and serotonin reuptake at the presynaptic terminal, producing a catecholamine flood: tachycardia, hypertension, agitation, mydriasis, hyperthermia.

Alpha-1 mediated coronary vasoconstriction and vasospasm , reducing supply at the moment demand peaks. Spasm can occur in angiographically normal arteries.

Enhanced platelet aggregation and thromboxane production plus accelerated atherosclerosis — chronic users develop premature obstructive coronary disease and true thrombotic occlusion.

Direct sodium-channel blockade (a class I antiarrhythmic effect) widening the QRS, plus potassium-channel blockade prolonging the QT.

The risk of myocardial infarction is roughly 24 times baseline in the first hour after use and remains elevated for hours; cocaine's half-life is short (about 45–90 minutes) but the metabolites benzoylecgonine and cocaethylene (formed when cocaine and alcohol are combined) prolong vasospasm for many hours, which is why chest pain can present long after the high has faded.

Presentations to recognize: cocaine-associated chest pain (most patients have non-ischemic causes, but 5–6% are having a true MI), STEMI in a young patient, cocaine cardiomyopathy (dilated, from repeated catecholamine injury and tachycardia), aortic dissection from the acute pressure surge, ventricular arrhythmia, seizure, intracerebral hemorrhage, hyperthermia with rhabdomyolysis, and pneumomediastinum from crack inhalation. Levamisole , a common adulterant, causes agranulocytosis and a retiform purpuric vasculitis.

Management — The Single Highest-Yield Rule

Priority Intervention Rationale

1. Benzodiazepines FIRST Diazepam 5–10 mg IV or lorazepam 2–4 mg IV , repeated and titrated They reduce central sympathetic outflow, so they simultaneously lower heart rate, blood pressure, temperature and myocardial oxygen demand and relieve chest pain. This is the answer to most cocaine questions

  • 2. Nitroglycerin Sublingual then IV infusion Reverses coronary vasoconstriction; combine with benzodiazepines
  • 3. Aspirin 162–325 mg chewed Addresses the platelet component
  • 4. Phentolamine 1–5 mg IV , repeatable Pure alpha blocker for refractory hypertension or persistent vasospasm

5. Calcium channel blockers Verapamil or diltiazem Second-line for vasospasm and rate; do not use as monotherapy for hypertension

6. Sodium bicarbonate 1–2 mEq/kg IV bolus for QRS above 100–120 ms Overcomes sodium-channel blockade — the same principle as tricyclic antidepressant overdose

7. Hyperthermia Aggressive external and evaporative cooling plus benzodiazepines ; paralysis if needed Antipyretics do not work because this is not a hypothalamic fever

Avoid Beta blockers acutely The teaching is unopposed alpha stimulation — blocking beta-2 vasodilation while alpha-1 vasoconstriction persists worsens coronary spasm and raises blood pressure. Contemporary evidence is genuinely debated and some centers use labetalol or carvedilol, but the AHA position and virtually every certification exam still follow the avoid rule. Answer accordingly

Reperfusion for cocaine STEMI follows standard pathways with primary PCI preferred; thrombolysis carries added hemorrhagic risk in an uncontrolled hypertensive patient and does not address spasm.

Methamphetamine produces the same catecholamine syndrome with a much longer half-life (about 10–12 hours), so agitation, hypertension and hyperthermia persist far longer. It is a leading cause of methamphetamine-associated cardiomyopathy in young adults (often severely reduced EF with a real chance of recovery on abstinence) and of drug-induced pulmonary arterial hypertension . Management principles mirror cocaine: benzodiazepines, cooling, vasodilators, and hydration for rhabdomyolysis.

Alcohol

Chronic cardiac effects:

Alcoholic cardiomyopathy — dilated cardiomyopathy after sustained heavy intake (classically more than about 80 g of ethanol daily for over 5 years). It can improve substantially with abstinence, which makes the conversation a therapeutic intervention.

Holiday heart syndrome — new atrial fibrillation or other supraventricular arrhythmia after a binge, often in a structurally normal heart, typically converting spontaneously within 24 hours. Alcohol also drives recurrent AF in established patients, and reduction is a guideline-endorsed rhythm-control strategy.

Hypertension — alcohol is one of the most common reversible contributors to resistant hypertension.

Wet beriberi — thiamine deficiency causing high-output heart failure with warm extremities, wide pulse pressure, peripheral edema and lactic acidosis. Give thiamine 100–500 mg IV before or with any glucose load ; giving dextrose first can precipitate Wernicke encephalopathy.

Withdrawal Timeline

  • Time from last drink Syndrome Features
  • 6–24 hours Minor withdrawal Tremor, anxiety, insomnia, diaphoresis, nausea, tachycardia and hypertension

12–24 hours Alcoholic hallucinosis Visual, tactile or auditory hallucinations with a clear sensorium and normal vital signs — this is what distinguishes it from delirium tremens

12–48 hours Withdrawal seizures Generalized tonic-clonic, usually one to three, short postictal period; status epilepticus is rare and suggests another cause

48–96 hours (up to 5–7 days) Delirium tremens Clouded sensorium and disorientation, severe agitation, hallucinations, fever, marked tachycardia, hypertension and diaphoresis ; mortality roughly 1–5% treated and far higher untreated

Assessment and treatment. The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, revised) scores 10 items to a maximum of 67; treatment is generally triggered at 8–10 or above , with scores above 15–20 indicating severe withdrawal. Symptom-triggered dosing — reassess and dose only when the score exceeds threshold — reduces total benzodiazepine exposure and shortens withdrawal versus fixed schedules, and is the preferred approach in a patient who can be reliably assessed. The CIWA-Ar is invalid in an intubated, sedated or non-communicative patient; use a benzodiazepine-based protocol with an objective sedation scale instead.

Benzodiazepines are the only class proven to prevent withdrawal seizures and delirium. Longer-acting agents (diazepam, chlordiazepoxide) give a smoother taper; lorazepam, oxazepam and temazepam are preferred in hepatic impairment and in the elderly because they undergo glucuronidation only, with no oxidative metabolism.

Phenobarbital is an effective adjunct or alternative in benzodiazepine-refractory withdrawal.

Dexmedetomidine blunts the sympathetic surge (useful when tachycardia and hypertension are threatening a fresh graft or stent) but is an adjunct only — it does not prevent seizures or delirium and must not replace benzodiazepines.

Add thiamine, folate, magnesium and potassium ; hypomagnesemia is nearly universal and lowers the seizure threshold.

Why this matters in a cardiac bed. Withdrawal typically peaks on hospital day 2–4 , which is exactly when the patient is 48 hours post-PCI or post-CABG. The autonomic surge produces tachycardia and hypertension that increase myocardial oxygen demand, stress fresh anastomoses and suture lines, precipitate post-operative atrial fibrillation, raise bleeding risk, and cause the agitated patient to pull lines, chest tubes and pacing wires. Alcohol withdrawal is one of the leading contributors to post-cardiotomy delirium. Ask about alcohol on admission — before the elective case, not on day 3.